AACR/ASCO JOINT CONFERENCE
Basic and Clinical Aspects of Lymphoma

January 10-14, 1997
Renaissance Esmeralda Resort
Indian Wells (Palm Springs), CA

Supported by a Generous Educational Grant from the
Cure For Lymphoma Foundation
(Corporate Support to be Listed in Future Announcements)

CONFERENCE CO-CHAIRPERSONS
James O. Armitage / Omaha, NE           Joseph R. Bertino / New York, NY

HONORARY CHAIRPERSON
Saul A. Rosenberg / Stanford, CA

PROGRAM COMMITTEE
Franco G. Cavalli / Bellinzona, Switzerland
Raju S. K. Chaganti / New York, NY
Thomas M. Grogan / Tucson, AZ
Ronald Levy / Stanford, CA
Bruce A. Chabner / Boston, MA
Richard I. Fisher / Maywood, IL
Alexandra M. Levine / Los Angeles, CA
Sharon B. Murphy / Chicago, IL

CONFERENCE PROGRAM

Keynote Address
Saul A. Rosenberg / Stanford, CA

The New Entities and Classification
Nancy L. Harris / Boston, MA
Dennis D. Weisenburger / Omaha, NE
James O. Armitage / Omaha, NE
Richard I. Fisher / Maywood, IL

Lymphomagenesis and Etiology
Franco G. Cavalli / Bellinzona, Switzerland
Richard F. Ambinder / Baltimore, MD

Lymphoma Associated with Immunodeficiency
Daniel Knowles / New York, NY
Lode J. Swinnen / Maywood, IL
Alexandra M. Levine / Los Angeles, CA

Genetic Abnormalities in Lymphoma
Raju S. K. Chaganti / New York, NY
Riccardo Dalla-Favera / New York, NY
Stephan W. Morris / Memphis, TN
Diane C. Louie / New York, NY

Cell Adhesion and Cell Signaling/
Molecular and Homing Receptors
Thomas M. Grogan / Tucson, AZ
Douglas R. Green / San Diego, CA

Can We Improve Outcome with Available Therapies?
Sharon B. Murphy / Chicago, IL
Joseph R. Bertino / New York, NY
John H. Glick / Philadelphia, PA

New Therapies
Bruce A. Chabner / Boston, MA
Oliver W. Press / Seattle, WA
Ronald Levy / Stanford, CA
Finbarr E. Cotter / London, England

Additional Speakers to be Announced

Applicants are encouraged to submit abstracts for oral and poster presentation.

Application Deadline: November 25, 1996

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300   215-440-9313 (FAX)
World Wide Web: http://www.aacr.org
CELL SIGNALING AND CANCER TREATMENT

An American Association for Cancer Research Special Conference in Collaboration with Austrian Cancer Society, British Association for Cancer Research, German Cancer Society and the Austrian Biochemical Society

February 23-28, 1997
Interalpen-Hotel Tyrol
Telfs-Buchen, Austria

CONFERENCE CHAIRPERSONS
Hans H. Grunicke / Innsbruck, Austria
Garth Powis / Tucson, USA
Paul Workman / Macclesfield, England

PROGRAM COMMITTEE
Sara A. Courtneidge / Redwood City, USA
Sylvie Gisselbrecht / Paris, France
Bernd Groner / Freiburg, Germany
Adrian L. Harris / Oxford, England
Peter A. Herrlich / Karlsruhe, Germany
Axel Ullrich / Munich, Germany
Peter Hilgard / Frankfurt, Germany
Alex Matter / Basel, Switzerland
Frank P. McCormick / Richmond, USA
Laurent Meijer / Roscoff, France
Michael J. Morin / Groton, USA

Keynote Address
Paul Workman / Macclesfield, England

Growth Factor Antagonists and Growth Factor Receptor Blockers
Enrique Rozengurt / London, England
Nancy E. Hynes / Basel, Switzerland
Bernd Groner / Freiburg, Germany
Nicholas Lydon / Basel, Switzerland

Receptor and Post Receptor Signaling: Mechanisms and Targets in Cancer Chemotherapy
Sara A. Courtneidge / Redwood City, USA
Frank P. McCormick / Richmond, USA
Nicholas K. Tonks / Cold Spring Harbor, USA
Garth Powis / Tucson, USA
Ulf R. Rapp / Würzburg, Germany
Alan K. Hall / London, England
Axel Ullrich / Munich, Germany

Cell Cycle and Cancer
Laurent Meijer / Roscoff, France
Christian Brechot / Paris, France
Rolf Müller / Marburg, Germany
J. Wade Harper / Houston, USA

Cytokine Signaling
Sylvie Gisselbrecht / Paris, France
Atsushi Miyayama / Tokyo, Japan
Ian M. Kerr / London, England
Gennaro Ciliberto / Rome, Italy

Programmed Cell Death: Role in Oncogenesis and Tumor Therapy
Gerard I. Evan / London, England
Caroline Dive / Manchester, England
Douglas R. Green / La Jolla, USA
Donald W. Nicholson / Pointe-Claire-Dorval, Quebec, Canada

Invasion and Metastasis
Max M. Burger / Basel, Switzerland
Louise E. Reichardt / San Francisco, USA
John G. Collard / Amsterdam, The Netherlands
Helmut Ponta / Karlsruhe, Germany

Angiogenesis
Adrian L. Harris / Oxford, England
Kari K. Alitalo / Helsinki, Finland
Isaiah J. Fidler / Houston, USA

Applicants are encouraged to submit abstracts for poster presentation.

Application deadline: November 1, 1996

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: aacr@aol.com
PLENARY SESSION
Genetic Predisposition to Cancer (Louise C. Strong)

SYMPOSIA
Genes, Cell Proliferation, and Antineoplastic Drugs
(George F. Vande Woude)
Diagnostic, Prognostic, and Therapeutic Aspects of
Tumor Suppressor Genes (David Sidransky)
Cell Cycle Regulation
Breast Cancer Genes (Barbara L. Weber)
Metastasis, Adhesion, and Angiogenesis: Mechanisms and
Therapeutic Strategies (Marilyn M. Cornwell)
Novel Clinical Trials Based on Genetics and Molecular
Therapeutics (Stephen H. Friend)
Apoptosis and Cancer Chemotherapy (Michael B. Kastan)
Identification and Management of Genetic-High-Risk
Individuals (Albert de la Chapelle)
Demythifying the Role of Cytokines in Tumor Immunobiology:
Status and Future Utility (Michael A. Caligiuri)
Telomerase and Clinical Applications (Titia de Lange)
Acute Myelocytic Leukemia (Clara Derber Bloomfield)
Prostate Cancer (Donald S. Coffey)
Colon Cancer (Margaret A. Tempo)
Signaling Pathways for Novel Therapeutics (Anthony J. Pawson)
Animal Models for Functional Analysis of Tumor Suppressor
Genes (Terry A. Van Dyke)
New Techniques for Molecular Diagnostics (Eric S. Lander)
Mechanisms of Cellular Senescence (J. Carl Barrett)
Damage Response Pathways (Philip C. Hanawalt)
Gene Interactions with the Environment/Carcinogenesis (Allan
Balmann)
Epidemiology and Pathogenesis of Secondary Cancers
(Frederick P. Li)

CONTROVERSIES SESSIONS
What Are the Appropriate Therapeutic Uses of Hematopoietic
Growth Factors? (Peter J. Quesenberry)
Estrogen Replacement Therapy: Beneficial or Harmful?
What is the Value of Mammography in Young and Genetically
Susceptible Women?
Is the Time Right for Cancer Chemoprevention? (Edward
Bresnick)
Gene Patents: Help or Hindrance to Conquering Cancer?
What is the Role of Prophylactic Surgery in Breast and Ovarian
Cancer? (Samuel A. Wells, Jr.)
What Are the Appropriate Guidelines for the Use of Archived
Human Tissue?
How Robust Are Antisense/Third Strand Techniques for Gene
Disruption?

"MEET-THE-EXPERT" SUNRISE SESSIONS
Angiogenesis
Gene Therapy (Jack A. Roth)
Strategies for Drug Development
Advances in Our Molecular Understanding of
Lymphoproliferative Disease (A. Thomas Look)
FHIT Gene (Kay Huebner)
Cancer Vaccines (David P. Carbone)
Lung Cancer
Costimulatory Molecules in Tumor Immunity
New Approaches to Overcoming Multidrug Resistance (Alan F.
List)
Advances in Oncologic Imaging
Retinoids and Cancer Prevention (Waun Ki Hong)
p53 Gene Mechanisms
p53 and Genetic Instability (Geoffrey Wahl)
Farnesyl Transferase Inhibitors (Allen I. Oliff)
Bioinformatics/Genomics
DNA Methylation in Cancer (Stephen B. Baylin)
Chemoprevention in Transgenic Animals (James M. Phang)
Advances in Stem Cell Transplantation
Psychosocial Issues in Cancer
Advances in the Management of AIDS-related Malignancies
(Ellen G. Feigal)
Recent Developments in Our Understanding of Minimal
Residual Disease (John G. Gribben)
Ovarian Cancer Update (Robert C. Bast, Jr.)
The Biological Basis of the New International Classification of
Lymphoma
Recent Developments in Radiotherapy
Colon Cancer Genes
Extracellular Connections
Barrett's Esophageal Cancer and Tumor Progression Models
H. Pylori
Transcriptional Models and Drug Discovery

METHODS WORKSHOPS AND EDUCATIONAL SESSIONS
To be announced

Abstract Deadline: November 12, 1996

Further Information: AACR Office • Public Ledger Building • Suite 816
• 150 S. Independence Mall West • Philadelphia, PA 19106-3483 •

TELEPHONE: (215) 440-9300 • FAX: (215) 440-9313 • Email:
aacr@aol.com

For up-to-date information visit the AACR web site at
http://www.aacr.org
Among the unique contributions of Rudolph Ludwig Karl Virchow (1821–1902) was the first true description of the cellular pathology of leukemia. He noted the irreversible progressive augmentation of the white blood cells, followed in later stages by a diminution of the red blood cells, and followed invariably by death. He described in meticulous detail the observation that the disease was accompanied by enormous enlargement of the lymphatic glands and spleen, owing to the accumulation of large numbers of cells. He studied microscopically the cellular anatomy of the leukemic leukocytes, as excerpted from Chapter 8 of his book, a classic compendium of 20 chapters entitled Cellular Pathology: As Based on Physiological and Pathological History. The book was published originally in Berlin in 1859, and an English translation was published in Philadelphia 4 years later. It was reprinted in New York as recently as 1971 and is noted for the first meticulous drawings of leukemia cells from the lymph glands and spleen, the tissues Virchow mistakenly regarded as the site of their origin.

Dr. Virchow was born in 1821 in Pomerania in the former East Germany. His father, a farmer and part-time town treasurer, supervised his early education. At the gymnasium, he displayed two lifelong characteristics: academic brilliance and rebellion against established rules. He then began his study of medicine in Berlin, where his scientific interests were shaped by the foremost German medical scientist, Johannes Müller. Upon graduation in 1843, he began his medical career at the Charité Hospital. Appalled by the poverty and starvation of the peasants he treated, he became thoroughly committed to the overthrow of the bureaucratic-feudal government and was a sympathetic but minor participant in the German Revolution in 1848. Removed from his post at the Charité Hospital, he went to the more intellectual climate at Wurzburg.

He spent 7 years as Chairman of the Pathology Department of the University of Wurzburg and then returned to Berlin to serve as Professor of Pathology and Director of the Pathological Institute. His academic career was marked by inspired teaching and an astonishing number of notable accomplishments. These included the discovery of narcotic and aspergillic forms of mycoses in lung and bronchi and the introduction of such major concepts as embolism, identification of neuroglia, the lymphatic sheaths of the cerebral arteries, rheumatic gout as arthritic deformans, the investigation of “lupus tuberculosi,” and a host of other entities. In 1861, he was elected to the Prussian Diet, and although his political interests dominated, he also contributed to the field of anthropology. In 1880, he was elected to the Reichstag, where he remained until 1893. By that time, his tremendous medical contributions had brought international acclaim and honors. As a “Renaissance man,” his brilliance extended widely. Following a fractured femur at age 81, his health declined rapidly, and he died in 1902.

Information for this legend was obtained by permission from Classics in Oncology, collected by Ca—A Cancer Journal for Clinicians, which was published in 1987 by the American Cancer Society, and edited by Arthur I. Holleb, M.D., and Michael Braun Randers-Pehrson, to whom our appreciation is extended.

Sidney Weinhouse